Investing.com UK - Financial Markets Worldwide
⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

[Infographic] DEA's Proposed Rules For Marijuana: What You Need To Know

Published 20/05/2024, 16:02
© Reuters. [Infographic] DEA's Proposed Rules For Marijuana: What You Need To Know

Benzinga - by Javier Hasse, Benzinga Editor.

The Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) have proposed a groundbreaking change to the federal scheduling of marijuana, aiming to reclassify it from Schedule I to Schedule III of the Controlled Substances Act (CSA). This move, detailed in a formal notice of proposed rulemaking, reflects the evolving scientific understanding and legal landscape surrounding marijuana, acknowledging its medical use and comparatively lower potential for abuse.

Historic Shift In Marijuana Policy

Initially classified as a Schedule I substance in 1970, marijuana has been a focal point of debate and petition for rescheduling. The last major review in 2016 upheld its Schedule I status, citing high potential for abuse and no accepted medical uses. However, the legal landscape has significantly changed, with 38 U.S. states and several territories legalizing medical marijuana, prompting a reexamination by federal agencies.

Timeline Of Marijuana's Federal Scheduling History

To use this infographic, please link to Benzinga.com/cannabis

Key Points From The Proposal The Department of Health and Human Services (HHS) conducted a comprehensive evaluation, leading to the recommendation to reschedule marijuana based on the following eight factors:

  • Potential for Abuse:
    • Lower potential for abuse compared to substances in Schedule I and II.
    • Epidemiological data shows lower rates of adverse outcomes compared to heroin and cocaine.
  • Pharmacological Effects:
    • Δ9-THC acts on CB1 and CB2 receptors in the brain and peripheral tissues.
    • Produces both rewarding (euphoria) and adverse effects (sedation, anxiety).
  • Current Scientific Knowledge:
    • Significant variation in chemical profiles across different marijuana strains.
    • Increased potency over the past few decades.
  • History and Pattern of Abuse:
    • Widespread use for medical and recreational purposes.
    • Lower incidence of severe medical outcomes compared to other controlled substances.
  • Scope and Significance of Abuse:
    • Abuse produces clear harmful consequences but less severe than other substances.
  • Risk to Public Health:
    • Public health risks are lower compared to drugs like heroin and cocaine.
  • Dependence Liability:
    • Moderate or low physical dependence and high psychological dependence.
  • Immediate Precursor:
    • Marijuana is not an immediate precursor of a controlled substance.
    • Proposal Details
    • Regulatory Controls: Rescheduling to Schedule III would impose regulatory controls and restrictions applicable to Schedule III substances.
    • Public Participation: Comments and requests for hearings must be submitted electronically or postmarked within 60 days of the publication in the Federal Register.
    Implications Of Rescheduling Medical Research and Use:

    • Enhanced ability for researchers to study marijuana's therapeutic potential.
    • More robust data on efficacy and safety could lead to new medical applications.
    Legal and Regulatory Landscape:

    • State-legal marijuana programs would remain, but with new federal regulations.
    • Potential for changes in how marijuana-related offenses are prosecuted.
    Economic Impact:

    • Shift in market dynamics for marijuana-related businesses.
    • Potential increase in investment and development within the cannabis industry.
    Public Participation And Next Steps The DOJ and DEA are actively seeking public comments and requests for hearings to ensure a comprehensive evaluation. The proposal outlines a detailed process for submitting feedback, emphasizing the importance of public involvement.

    Submission Guidelines:

    • Electronic Comments: Submit through the Federal eRulemaking Portal at regulations.gov.
    • Paper Comments: Mail to DEA Federal Register Representative at 8701 Morrissette Drive, Springfield, Virginia.
    • Hearing Requests: Send to the DEA Administrator at the same address, with a courtesy copy to the Hearing Clerk/OALJ.
    Key Differences Between Schedule I And Schedule III

    CriteriaSchedule ISchedule III
    Potential for Abuse High Lower than Schedule I and II
    Accepted Medical Use No Yes
    Dependence Risk High Moderate to low physical, high psychological
    Examples Heroin, LSD, Ecstasy Anabolic steroids, ketamine, codeine

    Eight-Factor Analysis Summary

    FactorDetails
    Potential for Abuse Lower compared to Schedule I and II substances
    Pharmacological Effects Δ9-THC acts on CB1 and CB2 receptors, produces euphoria and anxiety
    Current Scientific Knowledge Variable chemical profiles, increased potency over time
    History and Pattern of Abuse Widespread use, lower incidence of severe outcomes
    Scope and Significance of Abuse Harmful consequences less severe than other controlled substances
    Risk to Public Health Lower compared to drugs like heroin and cocaine
    Dependence Liability Moderate to low physical, high psychological
    Immediate Precursor Not an immediate precursor

    The proposed rescheduling of marijuana to Schedule III represents a pivotal moment in federal drug policy, potentially transforming the landscape for medical research, legal regulations, and the cannabis industry. Public participation is crucial in shaping the final decision, marking a significant step towards aligning federal regulations with evolving scientific and societal views on marijuana.

    This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Lead image generated by AI. Infographic by Javier Hasse.

    © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Read the original article on Benzinga

    Latest comments

    Install Our App
    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.